1. Epigenetics
    Stem Cell/Wnt
    JAK/STAT Signaling
  2. JAK

Itacitinib (Synonyms: INCB039110)

Cat. No.: HY-16997 Purity: 99.87%
Data Sheet SDS Handling Instructions

Itacitinib (INCB039110) is an oral selective JAK1 inhibitor.

For research use only. We do not sell to patients.
Itacitinib Chemical Structure

Itacitinib Chemical Structure

CAS No. : 1334298-90-6

Size Price Stock Quantity
10 mM * 1 mL in DMSO $426 In-stock
1 mg $150 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
50 mg $1500 In-stock
100 mg $2100 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Itacitinib (INCB039110) is an oral selective JAK1 inhibitor. Target: JAK1 in vitro: Itacitinib is an inhibitor of the Janus kinases (JAKs) with selectivity for JAK1. Itacitinib potently inhibits OCT2-mediated uptake of creatinine as well as MATE1-/MATE2-K-mediated efflux of creatinine. Itacitinib causes a dose-dependent decrease in transcellular transport of creatinine with weaker net inhibition compared with the effects on individual transporters.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02917993 Incyte Corporation|AstraZeneca Non-Small Cell Lung Cancer November 2016 Phase 1|Phase 2
NCT01634087 Incyte Corporation Chronic Plaque Psoriasis June 2012 Phase 2
NCT01626573 Incyte Corporation Rheumatoid Arthritis March 2012 Phase 2
NCT02257619 Incyte Corporation Non-Small Cell Lung Cancer June 2014 Phase 2
NCT02355431 Incyte Corporation Carcinoma|Non Small Cell Lung Cancer December 2014 Phase 2
NCT02909569 Washington University School of Medicine Pruritis November 2016 Phase 2
NCT02265510 Incyte Corporation Advanced Cancer August 2014 Phase 1|Phase 2
NCT03144687 Incyte Corporation Myelofibrosis July 2017 Phase 2
NCT02614612 Incyte Corporation Acute Graft Versus Host Disease December 2015 Phase 1
NCT01858883 Incyte Corporation Metastatic Cancer|Metastatic Pancreatic Cancer June 2013 Phase 1|Phase 2
NCT02760485 Incyte Corporation Diffuse Large B-cell Lymphoma December 2016 Phase 1|Phase 2
NCT03139604 Incyte Corporation Acute Graft-versus-host Disease June 8, 2017 Phase 3
NCT02456675 Incyte Corporation Refractory Hodgkin Lymphoma|Recurrent Adult Hodgkin's Lymphoma June 2015 Phase 2
NCT02018861 Incyte Corporation B-Cell Malignancies March 2015 Phase 1|Phase 2
NCT01905813 Incyte Corporation B-cell Malignancies June 2013 Phase 1
NCT02646748 Incyte Corporation Advanced Solid Tumors|Endometrial Cancer|Melanoma|Microsatellite Unstable (MSI) Colorectal Cancer|MMR-deficient Tumors|Non-small Cell Lung Cancer|Renal Cell Carcinoma|Head and Neck Squamous Cell Carcinoma|Triple Negative Breast Cancer|Transitional Cell Carcinoma of the Genitourinary Tract|Pancreatic Ductal Adenocarcinoma|Small Cell Lung Cancer January 2016 Phase 1
NCT02559492 Incyte Corporation Advanced Solid Tumors November 2015 Phase 1
NCT01633372 Incyte Corporation Primary Myelofibrosis|Post Polycythemia Vera Fibrosis|Post Essential Thrombocythemia Myelofibrosis April 2012 Phase 2
View MoreCollapse
Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 30 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.87%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: